Pfizer Inc. (PFE) - NYSE
  • Jan. 29, 2013, 7:01 AM
    Pfizer (PFE): Q4 EPS of $0.47 beats by $0.03. Revenue of $15.1B beats by $0.7B. (PR)
    | Jan. 29, 2013, 7:01 AM
  • Jan. 29, 2013, 12:05 AM

    Notable earnings before Tuesday’s open: AKS, ARLP, ASH, BSX, BTU, CIT, CP, DHI, EDU, EMC, F, GLW, GNTX, HOG, HRS, HW, IP, ITW, JBLU, KLIC, LLY, LXK, NEE, NUE, PFE, PHG, PII, PNR, TROW, TUP, TYC, VLO, WRB, X

    | Jan. 29, 2013, 12:05 AM
  • Jan. 28, 2013, 5:30 PM

    Notable earnings before Tuesday’s open: AKS, ARLP, ASH, BSX, BTU, CIT, CP, DHI, EDU, EMC, F, GLW, GNTX, HOG, HRS, HW, IP, ITW, JBLU, KLIC, LLY, LXK, NEE, NUE, PFE, PHG, PII, PNR, TROW, TUP, TYC, VLO, WRB, X

    | Jan. 28, 2013, 5:30 PM
  • Jan. 25, 2013, 4:27 PM

    Pfizer (PFE) says the FDA has approved the expansion of the it's pneumococcal conjugate vaccine, Prevnar 13, for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by 13 distinct Streptococcus pneumoniae serotypes contained in the vaccine.

    | Jan. 25, 2013, 4:27 PM
  • Jan. 24, 2013, 9:57 AM

    Pfizer (PFE +1.7%) comes out with a trio of positive study results for approved drugs: 8 mg of Tovia per day helped patients with overactive bladders more than 4 mg and a placebo; Pristiq met its main goal in sufferers of major depressive disorder; and Chantix can help smokers give up even if they have already but unsuccessfully used the drug before.

    | Jan. 24, 2013, 9:57 AM
  • Jan. 18, 2013, 12:26 PM

    Pfizer (PFE -1.4%) says the European Medicines Agency has issued a positive opinion on the conditional marketing authorization of its cancer drug bosutinib in the E.U. for the treatment of certain types of leukemia. Conditional approvals in the E.U. are granted to drugs that address unmet medical needs and whose availability would result in a significant public health benefit.

    | Jan. 18, 2013, 12:26 PM
  • Jan. 18, 2013, 4:51 AM

    More on IPO of Pfizer's (PFE) Zoetis (ZTS) unit: At the mid-point of its $22-25 price range, the animal-health business would be worth $11.8B, or 26 times earnings in the year to September 30. At the top end of the range, Zoetis, which is listing on the NYSE, would raise $2.15B. Pricing is scheduled for January 31.

    | Jan. 18, 2013, 4:51 AM | 3 Comments
  • Jan. 17, 2013, 5:26 PM

    Zoetis, Pfizer's (PFE) spinoff of its animal health unit, sees an IPO offering price of $22 to $25 per share. The Company plans to sell 86.1M shares under the ticker, "ZTS."

    | Jan. 17, 2013, 5:26 PM | 3 Comments
  • Jan. 15, 2013, 3:38 PM

    In preparation for Pfizer's (PFE -0.5%) planned spinoff of its animal-health company Zoetis, the drug giant beefs up its board with familiar name: William Steere, former CEO who presided over launch of anti-impotence pill Viagra in '90s and mega-deal that gave PFE full control of cholesterol blockbuster Lipitor. He stepped down as director in 2011 but it's no surprise that he's been summoned for duty again.

    | Jan. 15, 2013, 3:38 PM | 3 Comments
  • Jan. 15, 2013, 6:08 AM

    Looking to offset a patent cliff that could cut sales by up to $2.75B this year, Pfizer (PFE) is among the companies reportedly interested in acquiring Agila Specialties, the injectable-medicines unit of India's Strides Arcolab. Novartis (NVS), Mylan (MYL) and Fresenius (APCVZ) have also been eyeing Agila, which produces cancer treatments and antibiotics, and could be valued at $2B.

    | Jan. 15, 2013, 6:08 AM
  • Jan. 14, 2013, 1:28 PM

    Pfizer (PFE +0.7%) gets a lift today after saying it's made available its Quillivant XR, for the treatment of attention deficit hyperactivity disorder, in the U.S. Quillivant XR was approved by the FDA in September, 2012.

    | Jan. 14, 2013, 1:28 PM | 1 Comment
  • Jan. 14, 2013, 12:21 PM

    Halozyme Therapeutics (HALO +14%) gets a boost from an upgrade to Outperfrom at BMO Capital. The firm says meetings with management leave it increasingly confident in its pipeline, particularly the potential for a positive opinion for Herceptin SC in Q113. In addition, its recent collaboration with Pfizer (PFE +1%) will provide additional value drivers over the next 12 months.

    | Jan. 14, 2013, 12:21 PM
  • Jan. 8, 2013, 7:26 PM

    Nestle (NSRGY.PK) is looking to sell nearly $1B of its Latin American assets in an effort to secure regulatory approval for its $12B purchase of Pfizer's (PFE) nutrition unit. The company is in the early stages of the process, with the assets potentially drawing interest from H.J. Heinz (HNZ), Danone (DANOY.PK), Abbott Laboratories (ABT) and Mead Johnson Nutrition (MJN).

    | Jan. 8, 2013, 7:26 PM
  • Jan. 8, 2013, 6:15 PM

    Goldman Sachs' 23 best stocks for fat dividends and big buybacks: AIZ, UFS, VR, CCE, WYN, HFC, LOW, AMP, MPC, NSC, AXS, FITB, AMAT, PFE, JPM, DELL, RSG, PRU, BLK, CSX, GLW, TRV, CMCSA.

    | Jan. 8, 2013, 6:15 PM | 17 Comments
  • Jan. 8, 2013, 8:41 AM

    Pfizer (PFE -0.3%) receives EU approval to broaden the use of its Prevenar 13 drug for Pneumococcal Disease (PD) to children aged 6-17 from infants and young children. PD is an infection that can cause pneumonia, an infection of the blood, middle-ear infection and bacterial meningitis. (PR)

    | Jan. 8, 2013, 8:41 AM
  • Jan. 7, 2013, 5:33 PM
    The return of $10B-plus drug deals may be here as pharmaceutical companies appear to be gearing up to start buying again. Five of the largest U.S. drug makers have spent the last several years building up their cash positions in anticipation of expiring patents. Now, with nearly $70B in cash equivalents at their disposal, all eyes are on JPMorgan’s annual health-care conference in San Francisco, where the big drug makers will likely be on the hunt for assets to fill revenue holes left by expired patents.
    | Jan. 7, 2013, 5:33 PM | 2 Comments
Company Description
Pfizer, Inc. is a research-based, global biopharmaceutical company. The company's global portfolio includes medicines and vaccines, as well as many of the world's best-known consumer healthcare products. It collaborates with healthcare providers, governments and local communities to support and... More
Sector: Healthcare
Industry: Drug Manufacturers - Major
Country: United States